The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 02, 2014
Filed:
Mar. 03, 2008
Matthew Burger, Albany, CA (US);
Mika Lindvall, Oakland, CA (US);
Wooseok Han, San Ramon, CA (US);
Jiong Lan, Moraga, CA (US);
Gisele Nishiguchi, Albany, CA (US);
Cynthia Shafer, Moraga, CA (US);
Cornelia Bellamacina, Castro Valley, CA (US);
Kay Huh, San Mateo, CA (US);
Gordana Atallah, Fremont, CA (US);
Christopher Mcbride, San Diego, CA (US);
William Antonios-mccrea, Jr., Moraga, CA (US);
Tatiana Zavorotinskaya, Moraga, CA (US);
Annette Walter, Mill Valley, CA (US);
Pablo Garcia, Oakland, CA (US);
Matthew Burger, Albany, CA (US);
Mika Lindvall, Oakland, CA (US);
Wooseok Han, San Ramon, CA (US);
Jiong Lan, Moraga, CA (US);
Gisele Nishiguchi, Albany, CA (US);
Cynthia Shafer, Moraga, CA (US);
Cornelia Bellamacina, Castro Valley, CA (US);
Kay Huh, San Mateo, CA (US);
Gordana Atallah, Fremont, CA (US);
Christopher McBride, San Diego, CA (US);
William Antonios-McCrea, Jr., Moraga, CA (US);
Tatiana Zavorotinskaya, Moraga, CA (US);
Annette Walter, Mill Valley, CA (US);
Pablo Garcia, Oakland, CA (US);
Novartis AG, Basel, CH;
Abstract
New compounds, compositions and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.